Apollo Therapeutics Funding Round

9/7/2023

Venture Equity

$226,500,000

Series C

Proceeds will be used to advance pipeline programmes through clinical development and further fund Apollo's drug discovery and development activities based on breakthroughs in basic medical research at its partner institutions. Capital raised will also be used to licence or acquire additional clinical stage programmes that "meet strict selection criteria".

Private & Independent

Biopharmaceutical

3rd Floor 22 Station Road
Cambridge, England, CB1 2JD
UK

Undisclosed

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo's portfolio-based model combines a centralized team of drug development 'architects' and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner -- prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease.